FDA Quietly Retires 34 Forgotten Medicines
Published Date: 7/6/2026
Notice
Summary
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
34 Drug Approvals Withdrawn Aug 5, 2026
The FDA is withdrawing approval of 34 new drug applications (NDAs) as of August 5, 2026. After that date, introducing the listed products into interstate commerce would violate sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act.
On‑hand Inventory Can Still Be Dispensed
Drug products listed in the withdrawal may continue to be dispensed from existing inventory until those inventories are depleted, the products reach their expiration dates, or they otherwise become violative. This temporary allowance applies starting August 5, 2026.
Companies Waived Hearings; Can Refile
Applicants voluntarily requested withdrawal and waived their opportunity for a hearing; withdrawal under 21 CFR 314.150(c) is without prejudice to refiling, so companies may reapply for approval of these drugs in the future.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13519 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Devices
The FDA is asking for public feedback on their paperwork rules for approving the most important and risky medical devices, like life-support machines. This review helps keep devices safe and effective before they hit the market. If you have thoughts, you’ve got until August 5, 2026, to share them—no cost changes, just a check-in on the info they collect.
2026-13533 — Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements
The FDA wants your thoughts on how it collects info for biologics license applications—basically, the paperwork needed to approve new biological medicines. This affects companies making these medicines and anyone involved in the approval process. You’ve got until September 4, 2026, to share your comments, so don’t miss out on shaping the rules and possibly saving time and money!
2026-13492 — Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has confirmed that vasopressin in sodium chloride (0.9%, injection) wasn’t taken off the market because of safety or effectiveness problems. This means generic versions can now get approved if they meet all the rules, helping patients and healthcare providers get more options. No changes in price or availability are expected right now, but more generics could be coming soon!
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13346 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medication Guides for Prescription Drug Products
The FDA is updating how it collects info about Medication Guides—those important leaflets that come with some prescription drugs to keep patients safe. This affects drug makers who must follow new rules about what info to include and how to share it. Comments on these changes are open until July 31, 2026, and the update aims to keep patients informed without adding extra costs.
Previous / Next Documents
Previous: 2026-13615 — Draft Guidance for Reducing Risk From Perfluorooctanoic Acid (PFOA) and Perfluorooctane Sulfonic Acid (PFOS) in Biosolids; Establishment of a Public Docket; Request for Feedback
The EPA is sharing a draft guide to help wastewater plants, farmers, and water agencies reduce harmful chemicals called PFOA and PFOS in biosolids (treated sewage sludge). They want your thoughts on these ideas by September 4, 2026. While this guide isn’t a rule yet, it’s a big step toward safer soil and water, with no immediate costs but plenty of future benefits.
Next: 2026-13617 — New Postal Products
The Postal Service has asked for approval of new or changed special deals for competitive mail services. This affects businesses using these services and could change prices or options soon. Everyone has until July 8, 2026, to share their thoughts before the Postal Regulatory Commission makes a decision.